annual cash & cash equivalents:
$213.75M-$33.24M(-13.46%)Summary
- As of today (June 2, 2025), FOLD annual cash & cash equivalents is $213.75 million, with the most recent change of -$33.24 million (-13.46%) on December 31, 2024.
- During the last 3 years, FOLD annual cash & cash equivalents has fallen by -$31.45 million (-12.82%).
- FOLD annual cash & cash equivalents is now -13.46% below its all-time high of $246.99 million, reached on December 31, 2023.
Performance
FOLD Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$181.66M-$32.09M(-15.02%)Summary
- As of today (June 2, 2025), FOLD quarterly cash & cash equivalents is $181.66 million, with the most recent change of -$32.09 million (-15.02%) on March 31, 2025.
- Over the past year, FOLD quarterly cash & cash equivalents has dropped by -$28.10 million (-13.40%).
- FOLD quarterly cash & cash equivalents is now -52.93% below its all-time high of $385.90 million, reached on September 30, 2021.
Performance
FOLD quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
FOLD Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -13.5% | -13.4% |
| 3 y3 years | -12.8% | -22.1% |
| 5 y5 years | +49.6% | +47.4% |
FOLD Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -13.5% | +43.6% | -34.6% | +22.1% |
| 5 y | 5-year | -13.5% | +49.6% | -52.9% | +47.4% |
| alltime | all time | -13.5% | +3214.4% | -52.9% | +2716.7% |
FOLD Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $181.66M(-15.0%) |
| Dec 2024 | $213.75M(-13.5%) | $213.75M(-8.5%) |
| Sep 2024 | - | $233.65M(+11.6%) |
| Jun 2024 | - | $209.34M(-0.2%) |
| Mar 2024 | - | $209.76M(-15.1%) |
| Dec 2023 | $246.99M(+66.0%) | $246.99M(-6.2%) |
| Sep 2023 | - | $263.32M(+24.6%) |
| Jun 2023 | - | $211.31M(+31.6%) |
| Mar 2023 | - | $160.60M(+7.9%) |
| Dec 2022 | $148.81M(-39.3%) | $148.81M(-46.4%) |
| Sep 2022 | - | $277.59M(+17.8%) |
| Jun 2022 | - | $235.64M(+1.0%) |
| Mar 2022 | - | $233.32M(-4.8%) |
| Dec 2021 | $245.20M(+50.2%) | $245.20M(-36.5%) |
| Sep 2021 | - | $385.90M(+118.6%) |
| Jun 2021 | - | $176.54M(-4.5%) |
| Mar 2021 | - | $184.83M(+13.2%) |
| Dec 2020 | $163.24M(+14.3%) | $163.24M(-22.5%) |
| Sep 2020 | - | $210.63M(+28.0%) |
| Jun 2020 | - | $164.57M(+33.5%) |
| Mar 2020 | - | $123.23M(-13.7%) |
| Dec 2019 | $142.84M(+79.1%) | $142.84M(-14.1%) |
| Sep 2019 | - | $166.32M(-24.6%) |
| Jun 2019 | - | $220.58M(+128.9%) |
| Mar 2019 | - | $96.35M(+20.8%) |
| Dec 2018 | $79.75M(+62.6%) | $79.75M(-60.5%) |
| Sep 2018 | - | $201.83M(+175.3%) |
| Jun 2018 | - | $73.31M(-35.9%) |
| Mar 2018 | - | $114.32M(+133.0%) |
| Dec 2017 | $49.06M(-73.8%) | $49.06M(-23.5%) |
| Sep 2017 | - | $64.13M(+71.5%) |
| Jun 2017 | - | $37.39M(-16.4%) |
| Mar 2017 | - | $44.76M(-76.1%) |
| Dec 2016 | $187.03M(+169.2%) | $187.03M(+464.8%) |
| Sep 2016 | - | $33.12M(-48.0%) |
| Jun 2016 | - | $63.66M(+170.8%) |
| Mar 2016 | - | $23.51M(-66.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $69.48M(+188.6%) | $69.48M(+257.5%) |
| Sep 2015 | - | $19.44M(-92.2%) |
| Jun 2015 | - | $249.02M(+763.9%) |
| Mar 2015 | - | $28.83M(+19.7%) |
| Dec 2014 | $24.07M(-44.8%) | $24.07M(+22.4%) |
| Sep 2014 | - | $19.67M(-53.1%) |
| Jun 2014 | - | $41.90M(+52.2%) |
| Mar 2014 | - | $27.53M(-36.9%) |
| Dec 2013 | $43.64M(+28.5%) | $43.64M(+45.2%) |
| Sep 2013 | - | $30.05M(+28.0%) |
| Jun 2013 | - | $23.48M(-12.2%) |
| Mar 2013 | - | $26.74M(-21.3%) |
| Dec 2012 | $33.97M(+32.3%) | $33.97M(+40.0%) |
| Sep 2012 | - | $24.27M(-15.9%) |
| Jun 2012 | - | $28.86M(+17.7%) |
| Mar 2012 | - | $24.52M(-4.5%) |
| Dec 2011 | $25.67M(-13.2%) | $25.67M(+12.5%) |
| Sep 2011 | - | $22.81M(-11.6%) |
| Jun 2011 | - | $25.79M(-6.8%) |
| Mar 2011 | - | $27.66M(-6.5%) |
| Dec 2010 | $29.57M(+52.9%) | $29.57M(+33.8%) |
| Sep 2010 | - | $22.10M(-10.3%) |
| Jun 2010 | - | $24.62M(-26.6%) |
| Mar 2010 | - | $33.56M(+73.5%) |
| Dec 2009 | $19.34M(-31.1%) | $19.34M(-5.6%) |
| Sep 2009 | - | $20.49M(+30.0%) |
| Jun 2009 | - | $15.76M(-32.2%) |
| Mar 2009 | - | $23.24M(-17.2%) |
| Dec 2008 | $28.07M(-36.5%) | $28.07M(+41.4%) |
| Sep 2008 | - | $19.86M(+61.2%) |
| Jun 2008 | - | $12.31M(-32.3%) |
| Mar 2008 | - | $18.20M(-58.8%) |
| Dec 2007 | $44.19M(+264.4%) | $44.19M(+121.7%) |
| Sep 2007 | - | $19.93M(-24.8%) |
| Jun 2007 | - | $26.49M(+33.5%) |
| Mar 2007 | - | $19.85M(+63.7%) |
| Dec 2006 | $12.13M(+88.0%) | $12.13M(+88.0%) |
| Dec 2005 | $6.45M | $6.45M |
FAQ
- What is Amicus Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Amicus Therapeutics?
- What is Amicus Therapeutics annual cash & cash equivalents year-on-year change?
- What is Amicus Therapeutics quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Amicus Therapeutics?
- What is Amicus Therapeutics quarterly cash & cash equivalents year-on-year change?
What is Amicus Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of FOLD is $213.75M
What is the all time high annual cash & cash equivalents for Amicus Therapeutics?
Amicus Therapeutics all-time high annual cash & cash equivalents is $246.99M
What is Amicus Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, FOLD annual cash & cash equivalents has changed by -$33.24M (-13.46%)
What is Amicus Therapeutics quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of FOLD is $181.66M
What is the all time high quarterly cash & cash equivalents for Amicus Therapeutics?
Amicus Therapeutics all-time high quarterly cash & cash equivalents is $385.90M
What is Amicus Therapeutics quarterly cash & cash equivalents year-on-year change?
Over the past year, FOLD quarterly cash & cash equivalents has changed by -$28.10M (-13.40%)